Aurum Biosciences Ltd

Aurum Biosciences Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, developing novel oxygen carriers for use as both therapeutics and diagnostics. Its lead product, ABL-101, is an injectable oxygen carrier described by the company as 45 times smaller than a red blood cell — small enough to pass through blockages and small collateral vessels that stop red blood cells, carrying oxygen directly to dying tissue. The company positions ABL-101 as a dual-purpose platform: a therapy for acute ischaemic stroke and a diagnostic MRI metabolic and inflammation imaging agent. Aurum's founding story centres on addressing a major unmet medical need. According to the company, 90% of people suffering an acute stroke currently receive no direct treatment, because existing treatments cannot reach enough patients fast enough and safely enough. ABL-101 is intended to increase treatment to the vast majority of stroke patients. Beyond stroke, the company's broader mission targets oxygen deprivation across conditions such as heart attack, cardiac arrest, spinal cord injury, traumatic brain injury and oncology. ABL-101 has undergone significant pre-clinical development and has completed early Phase 1 and Phase 2 human studies, with the company reporting that it has been administered to 43 people across Phase 1 and Phase 2 studies with a good safety profile. It has previously received MHRA clinical trial approval in stroke. Two Phase 2 trials are planned for 2026/2027: a stroke trial in India assessing ABL-101's therapeutic, diagnostic and safety profile, and a carotid arteriosclerosis imaging trial in Switzerland, which has already been approved by SwissMedic. Aurum is backed by a range of investors including the Wellcome Trust, InnoScot Health, Tricapital Angels, Infinion Biopharma and Scottish Enterprise, alongside notable international and private investors. The company completed its final seed funding round in August 2025. It is headquartered at the Imaging Centre of Excellence at Queen Elizabeth University Hospital in Glasgow. The company is led by co-founder and CEO David, who has provided significant input into the development of ABL-101 both technically and commercially.

Aurum Biosciences Ltd was founded to develop novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS) and inflammation imaging. The company's founding story is rooted in the observation that most stroke patients receive no direct stroke treatment because existing treatments cannot reach enough patients fast enough and safely enough. Aurum set out to change that with a platform technology designed to deliver oxygen where blood cannot. The company's lead product, ABL-101, is an injectable oxygen carrier described as 45 times smaller than a red blood cell, small enough to slip past blockages and small collateral vessels that stop red blood cells and carry oxygen directly to dying tissue. ABL-101 has undergone significant pre-clinical development and has completed early Phase 1 and Phase 2 human studies. It has previously received MHRA clinical trial approval in stroke. According to the company, ABL-101 has been administered to 43 people across Phase 1 and Phase 2 studies, with a good safety profile. Aurum has attracted funding from a range of sources, including The Wellcome Trust, InnoScot, Tricapital Angel Investors, Scottish Enterprise and a number of notable international and private investors. The company recently completed its final seed funding round in August 2025. It is headquartered at the Imaging Centre of Excellence at Queen Elizabeth University Hospital in Glasgow, Scotland. As of the company's current disclosures, Aurum is a clinical-stage biopharmaceutical company with two Phase 2 trials planned to start soon: a stroke trial in India assessing ABL-101's therapeutic, diagnostic and safety profile, and a carotid arteriosclerosis imaging trial in Switzerland, which is already approved by SwissMedic. Two Phase 2 trials are described as underway in 2026, supported by Wellcome Trust and a growing international network of clinical collaborators. The company's long-term mission is to make ABL-101 a platform drug addressing oxygen deprivation across a wide range of serious conditions, including heart attack, traumatic brain injury, spinal cord injury, cardiac arrest and oncology.

• Completed final seed funding round

• Two Phase 2 trials planned/underway (stroke in India; carotid arteriosclerosis imaging in Switzerland)

Clinical-stage biopharmaceutical company developing a patented oxygen-carrier platform that acts as both therapy and diagnostic, initially targeting acute ischaemic stroke and inflammation imaging.

• ABL-101

  Injectable oxygen carrier 45 times smaller than a red blood cell; dual therapeutic and diagnostic (MRI metabolic and inflammation imaging) for acute ischaemic stroke and other oxygen-deprivation conditions.

1. 1Delivering Oxygen Where Blood Cannot |aurumbiosciences.com
2. 2About us | Delivering Oxygen Where Blood Cannotaurumbiosciences.com
3. 3Aurum Biosciences (United Kingdom) - Wikidatawikidata.org